CD8A and hematologic disorder: Future studies in hematologic malignancies should analyze CXCR5+PD‐1+ CD8 T cells within tumor‐specific CD8 T‐cell populations during PD‐1 ICB therapy to determine whether CXCR5+PD‐1+ CD8 T cells are a biomarker for therapeutic response.